Summit Therapeutics Inc. Number of Reportable Segments
Summit Therapeutics Inc. (SMMT) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-07-23
- Summit Therapeutics Inc. number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment.
- Summit Therapeutics Inc. number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- Summit Therapeutics Inc. number of reportable segments for fiscal 2024 was 1.00 segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 11 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-07-23 | ||||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-04-30 | ||||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | 1.00 segment 10-Q · filed 2025-10-20 | ||||
| 2025-06-30 | 1.00 segment 10-Q · filed 2025-08-11 | ||||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-02-24 | ||||
| 2020-09-30 | 1.00 segment 10-Q · filed 2020-11-16 | ||||
| 2020-06-30 | 1.00 segment 8-K · filed 2020-09-29 | ||||
| 2019-12-31 | 1.00 segment 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |